The United Laboratories International Holdings Limited

中/EN
中文繁體 English
  • Investor Relations
    IR Home Corporate Overview Financial Highlights Financial Reports ESG Reports Regulatory Filings Press Releases Company Presentations Stock Quotes & Charts Analyst Coverage FAQs IR Contact
  • Corporate
Investor Relations
  • IR Home
  • Corporate Overview
  • Financial Highlights
  • Financial Reports
  • ESG Reports
  • Regulatory Filings
  • Press Releases
  • Company
    Presentations
  • Stock Quotes &
    Charts
  • Analyst Coverage
  • FAQs
  • IR Contact

Press Releases

2021
Please select
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
AUG
27
The United Laboratories International Holdings Limited, Announces 2021 Interim Results, Profit Attributable to Shareholders up by 207.2% to RMB623.1 Million Insulin Series Products Maintained Steady Growth, Successfully Delivered First Batch of Insulin Aspart Products
JUL
15
TUL Receives Drug Registration Approval for Insulin Aspart, Enriching Portfolio of Diabetic Drugs
MAR
30
The United Laboratories International Holdings Limited, Announces 2020 Annual Results, Profit attributable to Shareholders up by 9.5% to RMB703 Million, Insulin Series Beat Sales Targets
Disclaimer | Sitemap

Copyright © 2019 The United Laboratories International Holdings Limited. All rights reserved.